Loading clinical trials...
Loading clinical trials...
A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Conditions
Interventions
TNX-102 SL 5.6 mg
Locations
16
United States
Little Rock
Little Rock, Arkansas, United States
Beverly Hills
Beverly Hills, California, United States
Oceanside
Oceanside, California, United States
Orange
Orange, California, United States
Temecula
Temecula, California, United States
Colorado Springs
Colorado Springs, Colorado, United States
Start Date
April 19, 2018
Primary Completion Date
September 30, 2019
Completion Date
September 30, 2019
Last Updated
February 5, 2025
NCT06956781
NCT07010757
NCT06804525
NCT07462312
NCT07351305
NCT07447089
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions